Immunomodulating antibodies and drugs for the treatment of hematological malignancies
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunomodulating antibodies and drugs for the treatment of hematological malignancies
Authors
Keywords
-
Journal
CANCER AND METASTASIS REVIEWS
Volume 30, Issue 1, Pages 97-109
Publisher
Springer Nature
Online
2011-01-27
DOI
10.1007/s10555-011-9274-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Anti-tumor effects of depleting and non-depleting anti-CD27 monoclonal antibodies in immune-competent mice
- (2010) Tamami Sakanishi et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells
- (2010) H. Narazaki et al. BLOOD
- Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma
- (2010) Greg Dueck et al. CANCER
- Clinical significance of B7-H1（PD-L1）expression in human acute leukemia
- (2010) Xiangli Chen et al. CANCER BIOLOGY & THERAPY
- A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma
- (2010) M. Hussein et al. HAEMATOLOGICA
- In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
- (2010) Joshua D. Brody et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia
- (2010) Richard R. Furman et al. LEUKEMIA & LYMPHOMA
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion
- (2009) R. Houot et al. BLOOD
- Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells
- (2009) F. Romagne et al. BLOOD
- Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma
- (2009) Jonathan W. Friedberg et al. BRITISH JOURNAL OF HAEMATOLOGY
- Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma
- (2009) Thomas M. Habermann et al. BRITISH JOURNAL OF HAEMATOLOGY
- Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma
- (2009) Boris Böll et al. BRITISH JOURNAL OF HAEMATOLOGY
- Phase I Study of Ipilimumab, an Anti-CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma
- (2009) S. M. Ansell et al. CLINICAL CANCER RESEARCH
- Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
- (2009) Thomas E. Witzig et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma
- (2009) Ranjana Advani et al. JOURNAL OF CLINICAL ONCOLOGY
- Incorporating the use of GM-CSF in the treatment of chronic lymphocytic leukemia
- (2009) Alessandra Ferrajoli LEUKEMIA & LYMPHOMA
- The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells
- (2008) M. Luqman et al. BLOOD
- Thalidomide and rituximab in Waldenstrom macroglobulinemia
- (2008) S. P. Treon et al. BLOOD
- Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells
- (2008) R. Lapalombella et al. BLOOD
- CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation
- (2008) A. Bashey et al. BLOOD
- Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia
- (2008) A. Ferrajoli et al. BLOOD
- Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B
- (2008) Sonali M. Smith et al. BRITISH JOURNAL OF HAEMATOLOGY
- Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells
- (2008) L. Wu et al. CLINICAL CANCER RESEARCH
- Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies
- (2008) R. Berger et al. CLINICAL CANCER RESEARCH
- Therapeutic Antitumor Efficacy of Anti-CD137 Agonistic Monoclonal Antibody in Mouse Models of Myeloma
- (2008) O. Murillo et al. CLINICAL CANCER RESEARCH
- Lenalidomide and Rituximab in Waldenstrom's Macroglobulinemia
- (2008) S. P. Treon et al. CLINICAL CANCER RESEARCH
- Treatment of Hematologic Neoplasms with New Immunomodulatory Drugs (IMiDs)
- (2008) Peter H. Wiernik CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Interleukin-21: biology and application to cancer therapy
- (2008) David J Andorsky et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Approved monoclonal antibodies for cancer therapy
- (2008) Michael Boyiadzis et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia
- (2008) Luc Xerri et al. HUMAN PATHOLOGY
- Granulocyte-Macrophage Colony-Stimulating Factor Potentiates Rituximab in Patients With Relapsed Follicular Lymphoma: Results of a Phase II Study
- (2008) Guillaume Cartron et al. JOURNAL OF CLINICAL ONCOLOGY
- Higher Doses of Lenalidomide Are Associated With Unacceptable Toxicity Including Life-Threatening Tumor Flare in Patients With Chronic Lymphocytic Leukemia
- (2008) Leslie A. Andritsos et al. JOURNAL OF CLINICAL ONCOLOGY
- OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection
- (2008) Silvia Piconese et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: A randomized phase II study from the Nordic Lymphoma Group
- (2008) Eva Kimby et al. LEUKEMIA & LYMPHOMA
- Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody
- (2008) R. Bargou et al. SCIENCE
- An Erythroid Differentiation Signature Predicts Response to Lenalidomide in Myelodysplastic Syndrome
- (2008) Benjamin L Ebert et al. PLOS MEDICINE
- NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma
- (2007) Esther Moga et al. EXPERIMENTAL HEMATOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now